ES2856555T3 - Procedimientos y composiciones farmacéuticas para el tratamiento de la fibrosis quística - Google Patents

Procedimientos y composiciones farmacéuticas para el tratamiento de la fibrosis quística Download PDF

Info

Publication number
ES2856555T3
ES2856555T3 ES16736045T ES16736045T ES2856555T3 ES 2856555 T3 ES2856555 T3 ES 2856555T3 ES 16736045 T ES16736045 T ES 16736045T ES 16736045 T ES16736045 T ES 16736045T ES 2856555 T3 ES2856555 T3 ES 2856555T3
Authority
ES
Spain
Prior art keywords
mir
nucleic acid
ano1
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16736045T
Other languages
English (en)
Spanish (es)
Inventor
Olivier Tabary
Florence Sonneville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2856555T3 publication Critical patent/ES2856555T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES16736045T 2015-07-03 2016-07-01 Procedimientos y composiciones farmacéuticas para el tratamiento de la fibrosis quística Active ES2856555T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2015/001253 WO2017006145A1 (en) 2015-07-03 2015-07-03 Methods and pharmaceutical compositions for the treatment of cystic fibrosis
PCT/EP2016/065565 WO2017005646A1 (en) 2015-07-03 2016-07-01 Methods and pharmaceutical compositions for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
ES2856555T3 true ES2856555T3 (es) 2021-09-27

Family

ID=54347575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16736045T Active ES2856555T3 (es) 2015-07-03 2016-07-01 Procedimientos y composiciones farmacéuticas para el tratamiento de la fibrosis quística

Country Status (5)

Country Link
US (1) US11130950B2 (https=)
EP (1) EP3317412B1 (https=)
JP (1) JP7032140B2 (https=)
ES (1) ES2856555T3 (https=)
WO (2) WO2017006145A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076919A1 (en) 2017-10-17 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) COMBINED TREATMENT OF CYSTIC FIBROSIS
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
WO2023152369A1 (en) * 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948926A (zh) 2014-03-24 2014-07-30 江苏大学 miR-9抑制剂在制备用于抑制肿瘤生长药物中的用途

Also Published As

Publication number Publication date
JP7032140B2 (ja) 2022-03-08
WO2017005646A1 (en) 2017-01-12
US11130950B2 (en) 2021-09-28
EP3317412B1 (en) 2020-12-02
WO2017005646A8 (en) 2017-10-19
WO2017006145A1 (en) 2017-01-12
EP3317412A1 (en) 2018-05-09
JP2018520150A (ja) 2018-07-26
US20200040332A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
Lv et al. lncMGPF is a novel positive regulator of muscle growth and regeneration
US11739308B2 (en) Cas13b orthologues CRISPR enzymes and systems
ES2739804T3 (es) Compuestos terapéuticos
AU2014351482B2 (en) C/EBP alpha short activating RNA compositions and methods of use
ES2969371T3 (es) Interferencia por ARN para el tratamiento de trastornos de ganancia de función
BR112019026226A2 (pt) composições compreendendo curóns e usos dos mesmos
Bardin et al. Emerging microRNA therapeutic approaches for cystic fibrosis
US20220133774A1 (en) Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor
ES2886147T3 (es) MiARN para el tratamiento del cáncer de cabeza y de cuello
BR112019009725A2 (pt) sistema de controle de função de sc artificialmente manipulado
ES2856555T3 (es) Procedimientos y composiciones farmacéuticas para el tratamiento de la fibrosis quística
Tan et al. MicroRNA-126a-5p exerts neuroprotective effects on ischemic stroke via targeting NADPH oxidase 2
JP6472807B2 (ja) 嚢胞性線維症の処置のための方法及び医薬組成物
BR112021012422A2 (pt) Molécula de ácido nucleico oligomérica e uso da mesma
CN111566212A (zh) miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
WO2015095116A1 (en) Compositions and methods for treating diabetic nephropathy
CN106974929A (zh) miR‑647在制备治疗胃癌的药物中的用途
CN119033802B (zh) 非编码调控性rna在制备预防或治疗癌症或组织纤维化疾病的药物中的用途
EP4616905A1 (en) Use of inhibitors of micrornas in the treatment of lung diseases
KR20200055723A (ko) 인슐린 저항성 검출 및 치료용 조성물 및 방법
Delemos Electroporation-Mediated Gene Delivery of CFTR Plasmids as a Novel Approach to Treat Cystic Fibrosis In Vivo
Baughn Therapeutic Restoration of Stathmin-2 RNA Processing in TDP-43 Proteinopathies
WO2023152369A1 (en) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
WO2025253282A1 (en) Small interfering nucletides (sioligo) for the treatment of cole-carpenter syndrome (ccs)
CN106434674B (zh) 一种微小分子RNA-758-3p及其作为抗肿瘤标志物的用途